Variation in Potency and Spectrum of Tigecycline Activity against Bacterial Strains from US Medical Centers since Its Approval for Clinical Use (2006 to 2012)
Variation in Potency and Spectrum of Tigecycline Activity against Bacterial Strains from US Medical Centers since Its Approval for Clinical Use (2006 to 2012)
复制标题
DOI：
10.1128/aac.02684-13
复制
发表时间：
2014-04-01
影响因子：
4.9
通讯作者：
Jones, Ronald N.
中科院分区：
文献类型：
--
作者：
Sader, Helio S.;Farrell, David J.;Jones, Ronald N.
替加环素最初于 2005 年 6 月获得美国食品和药物管理局 (FDA) 批准。我们通过分析美国 SENTRY 抗菌监测计划 7 年（2006 年至 2012 年）的数据结果，评估了替加环素自首次批准临床使用以来体外活性的演变。我们还分析了关键耐药表型随时间的变化趋势。分析包括从 29 个医疗中心收集的 68,608 个独特的临床分离株，并使用参考肉汤微量稀释方法进行敏感性测试。替加环素对革兰氏阳性菌具有高度活性，对金黄色葡萄球菌（28,278 株；>99.9% 敏感）的 MIC50 和 MIC90 值为 0.12 和 0.25 μg/ml，对肠球菌（99.3% 至 99.6% 敏感）的 MIC50 和 MIC90 值为 0.06 至 0.12 和 0.12 至 0.25 μg/ml，
Tigecycline was initially approved by the U.S. Food and Drug Administration (FDA) in June 2005. We assessed the evolution of tigecycline in vitro activities since the initial approval of tigecycline for clinical use by analyzing the results of 7 years (2006 to 2012) of data from the SENTRY Antimicrobial Surveillance Program in the United States. We also analyzed trends over time for key resistance phenotypes. The analyses included 68,608 unique clinical isolates collected from 29 medical centers and tested for susceptibility using reference broth microdilution methods. Tigecycline was highly active against Gram-positive organisms, with MIC50 and MIC90 values of 0.12 and 0.25 mu g/ml for Staphylococcus aureus (28,278 strains; >99.9% susceptible), 0.06 to 0.12 and 0.12 to 0.25 mu g/ml for enterococci (99.3 to 99.6% susceptible), and